ORCID as entered in ROS
https://orcid.org/0000-0002-1456-876X
Select Publications
Journal articles
, 2018, 'Barriers and facilitators of appropriate vancomycin use: prescribing context is key', European Journal of Clinical Pharmacology, 74, pp. 1523 - 1529, http://dx.doi.org/10.1007/s00228-018-2525-2
, 2018, 'Lactic Acidosis, Metformin Use, and Dose-Response Association', JAMA Internal Medicine, 178, pp. 1428 - 1429, http://dx.doi.org/10.1001/jamainternmed.2018.4448
, 2018, 'Clinical pharmacokinetics in kidney disease application to rational design of dosing regimens', Clinical Journal of the American Society of Nephrology, 13, pp. 1254 - 1263, http://dx.doi.org/10.2215/CJN.05150418
, 2018, 'Clinical pharmacokinetics in kidney disease: Fundamental principles', Clinical Journal of the American Society of Nephrology, 13, pp. 1085 - 1095, http://dx.doi.org/10.2215/CJN.00340118
, 2018, 'Patients' use of mobile health applications: What general practitioners think', Family Practice, 36, pp. 214 - 218, http://dx.doi.org/10.1093/fampra/cmy052
, 2018, 'Molecular Determinants for Substrate Interactions with the Glycine Transporter GlyT2', ACS Chemical Neuroscience, 9, pp. 603 - 614, http://dx.doi.org/10.1021/acschemneuro.7b00407
, 2018, 'A Multicentre Open-Label Pharmacokinetic-Pharmacodynamic Study of Febuxostat in Patients with Chronic Gout', Proceedings for Annual Meeting of The Japanese Pharmacological Society, WCP2018, http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_po1-11-12
, 2017, 'Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2', ACS Chemical Neuroscience, 8, pp. 1949 - 1959, http://dx.doi.org/10.1021/acschemneuro.7b00105
, 2017, 'Allopurinol: insights from studies of dose–response relationships', Expert Opinion on Drug Metabolism and Toxicology, 13, pp. 449 - 462, http://dx.doi.org/10.1080/17425255.2017.1269745
, 2016, 'Glycine transporter2 inhibitors: Getting the balance right', Neurochemistry International, 98, pp. 89 - 93, http://dx.doi.org/10.1016/j.neuint.2015.12.007
, 2016, 'Correction: Identification of a 3rd Na+ binding site of the glycine transporter, GlyT2', PLoS ONE, 11, http://dx.doi.org/10.1371/journal.pone.0159896
, 2016, 'Identification of a 3rd Na+ binding site of the glycine transporter, GlyT2', PLoS ONE, 11, pp. e0157583, http://dx.doi.org/10.1371/journal.pone.0157583
, 2015, 'Molecular Basis for Substrate and Inhibitor Interactions with the Glycine Transporter, GlyT2', FASEB JOURNAL, 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361470504039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'A Hydrophobic Area of the GABA ρ
, 2014, 'Glycine transport inhibitors for the treatment of pain', Trends in Pharmacological Sciences, 35, pp. 423 - 430, http://dx.doi.org/10.1016/j.tips.2014.05.006
, 2014, 'Lipid inhibitors of high affinity glycine transporters: Identification of a novel class of analgesics', Neurochemistry International, 73, pp. 211 - 216, http://dx.doi.org/10.1016/j.neuint.2013.08.012
, 2013, 'Mutagenic analysis of the intracellular portals of the human 5-HT
, 2013, 'Oleoyl-L-carnitine inhibits glycine transport by GlyT2', British Journal of Pharmacology, 168, pp. 891 - 902, http://dx.doi.org/10.1111/j.1476-5381.2012.02213.x
, 2012, 'Differentiating enantioselective actions of GABOB: A possible role for threonine 244 in the binding site of GABA
, 2012, 'Structurally diverse GABA antagonists interact differently with open and closed conformational states of the ρ
, 2010, 'Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors', Journal of Physiology, 588, pp. 587 - 596, http://dx.doi.org/10.1113/jphysiol.2009.183137
, 2010, 'External divalent cations increase anion-cation permeability ratio in glycine receptor channels', Pflugers Archiv - European Journal of Physiology, 460, pp. 131 - 152, http://dx.doi.org/10.1007/s00424-010-0792-6
, 2009, 'Characterization of the effects of charged residues in the intracellular loop on ion permeation in α1 glycine receptor channels', The Journal of Biological Chemistry, 284, pp. 2023 - 2030, http://dx.doi.org/10.1074/jbc.M806618200
, 2008, 'Relative impact of residues at the intracellular and extracellular ends of the human GABA(C) rho 1 receptor M2 domain on picrotoxinin activity', European Journal of Pharmacology, 580, pp. 27 - 35
, 2008, 'Structural determinants of Ca2+ permeability and conduction in the human 5-hydroxytryptamine type 3A receptor', The Journal of Biological Chemistry, 283, pp. 19301 - 19313
, 2007, 'Dynamic modification of a mutant cytoplasmic residue modulates the conductance of the human 5-HT3A receptor', The Journal of Biological Chemistry, 282, pp. 6172 - 6182, http://dx.doi.org/10.1074/jbc.M607698200
, 2006, 'Common determinants of single channel conductance within the large cytoplasmic loop of 5-HT3 and á4â2 nicotinic acetylcholine receptors', The Journal of Biological Chemistry, 281, pp. 8062 - 8071, http://dx.doi.org/10.1074/jbc.M513222200
, 2006, 'Novel structural determinants of single channel conductance in nicotinic acetylcholine and 5-hydroxytryptamine type-3 receptors', Biochemical Society Transactions, 34, pp. 882 - 886, http://www.biochemsoctrans.org/bst/034/0882/0340882.pdf
, 2005, 'Methyllycaconitine analogues have mixed antagonist effects at nicotinic acetylcholine receptors', Bioorganic and Medicinal Chemistry, 13, pp. 4565 - 4575, http://dx.doi.org/10.1016/j.bmc.2005.04.054
, 2004, 'Charged residues at the 2 ` position of human GABA(c) rho 1 receptorsinvert ion selectivity and influence open state probability', The Journal of Biological Chemistry, 279, pp. 54153 - 54160
, 2004, 'Mutations of the 2' proline in the M2 domain of the human GABAC ĉ1 subunit alter agonist responses', Neuropharmacology, 46, pp. 770 - 781, http://dx.doi.org/10.1016/j.neuropharm.2003.11.027
Conference Papers
, 2008, 'External divalent ions increase anion-cation permeability in glycine receptor channels – consideration of ion activities, surface charge and conductance measurements', in Proceedings of the Australian Physiological and Pharmacological Society, presented at
Conference Posters
, 2023, 'A novel practical class using crickets to demonstrate the pharmacological actions of drugs for third year neuropharmacology students', presented at ANS, 04 December 2023 - 07 December 2023
, 2023, 'Patient’s experience of a psychiatric, alcohol and non-prescription drug assessment (PANDA) unit', Sydney, presented at ASCEPT, Sydney, 20 November 2023 - 23 November 2023
, 2022, 'The trends and opinions of Australian clinicians on the use of antihyperglycemic agents in heart failure patients', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2022 - 29 November 2019
, 2021, 'Matters close to the heart: adaptation of a tacrolimus model to inform therapeutic drug monitoring using the PRIOR approach', Virtual, presented at American Conference on Pharmacometrics, Virtual, 08 November 2021 - 12 November 2021
, 2021, 'Matters close to the heart: adaptation of a tacrolimus model to inform therapeutic drug monitoring using the PRIOR approach', Virtual, presented at IATDMCT, Virtual, 19 September 2021 - 22 September 2021
, 2021, 'Matters close to the heart: adaptation of a tacrolimus model to inform therapeutic drug monitoring using the PRIOR approach', Virtual, presented at Population Approach Group Europe, Virtual, 02 September 2021 - 07 September 2021
, 2020, 'Predictive performance of population pharmacokinetic models for tacrolimus in lung transplant recipients', Virtual, presented at ASCEPT, Virtual, 29 November 2020 - 02 December 2020
, 2020, 'A step forward in patient safety - understanding barriers to correct intravenous medication administrations', Virtual, presented at ASCEPT, Virtual, 29 November 2020 - 02 December 2020
, 2020, 'External evaluation of population pharmacokinetic models of tacrolimus in adult heart transplant recipients', presented at Pharmacometrics Japan, 22 January 2020 - 23 January 2020
, 2019, 'Accuracy of documented administration times for intravenous antimicrobial drugs', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019
, 2019, 'Barriers and facilitators to user acceptance of a pilot therapeutic drug monitoring advisory service for vancomycin', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019
, 2019, 'External evaluation of published population pharmacokinetic models of tacrolimus in adult heart transplant recipients', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019
, 2019, 'Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review', Queenstown, New Zealand, presented at ASCEPT-PAGANZ, Queenstown, New Zealand, 25 November 2019 - 29 November 2019
, 2019, 'Designing a therapeutic drug monitoring (TDM) advisory service for vancomycin: identifying barriers and facilitators to service implementation', Darwin, Australia, presented at ASID, Darwin, Australia, 16 May 2019 - 18 May 2019
, 2019, 'Predictive performance of a commercial Bayesian forecasting program in estimating vancomycin drug exposure', Washington DC, USA, presented at American Society for Clinical Pharmacology and Therapeutics, Washington DC, USA, 14 March 2019 - 16 March 2019
, 2018, 'Comparison of vancomycin area-under-the-curve using one and two-compartment pharmacokinetic models', Adelaide, Australia, presented at ASCEPT, Adelaide, Australia, 27 November 2018 - 30 November 2018
, 2018, 'Predictive performance of tacrolimus precision dosing software', Adelaide, Australia, presented at ASCEPT, Adelaide, Australia, 27 November 2018 - 30 November 2018
, 2018, 'Tacrolimus Dosing and Monitoring in Lung Transplant Patients', Adelaide, Australia, presented at ASCEPT, Adelaide, Australia, 27 November 2018 - 30 November 2018
Filter by type
https://orcid.org/0000-0002-1456-876X